FDA Will Delay Food Safety Reforms on Farmer Concerns

Food and Drug Administration says it will revise FSMA rule language and seek comment in the summer

Published on: Dec 20, 2013

Rules governing food safety and handling on the farm level will be revised and delayed until early next summer, a Food and Drug Administration official said Thursday.

In question are the Produce Rule and Preventive Controls Rule, both part of the 2011 Food Safety Modernization Act. They include a sweeping set of reforms that would have a significant impact on farmers' management of produce and compliance to new food safety regulations.

"Based on our discussions with farmers, the research community and other input we have received, we have learned a great deal, and our thinking has evolved," FDA Deputy Commissioner for Foods and Veterinary Medicine Michael Taylor explained in an FDA statement.

Food and Drug Administration says it will revise FSMA rule language and seek comment in the summer
Food and Drug Administration says it will revise FSMA rule language and seek comment in the summer

"Everyone shares the goal of ensuring produce safety, but, as we said at the beginning of the process, the new safety standards must be flexible enough to accommodate reasonably the great diversity of the produce sector, and they must be practical to implement," he said.

As Taylor addressed, farm and produce groups at the front of the debate supported attention to advanced food safety, but said the rules were too restrictive, instituting new requirements that conflict with existing conservation and environmental standards.

Groups also pointed to the "unintended consequences" that could result from FSMA regulations as proposed, including regulations that did not respect the varying production practices that farmers use to raise a variety of crops.

The National Sustainable Agriculture Coalition took significant concern with FDA's economic costs of implementation and how federal and state agencies would work together to implement the new regulations.

Even though most of the discussion centered on the fundamentals of the rules, that wasn't the only issue at hand. The FDA has previously caught attention for its handling of the rules' draft language release and comment periods.